CAS · 941678-49-5
Product Overview
Ruxolitinib is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Property | Specification |
|---|---|
| Appearance | Off white to light yellow crystalline powder |
| Purity (HPLC) | 99% min. |
| Identification HPLC | In the chromatogram recorded under the relevant substance item, the retention time of the main peak of the test solution should be consistent with that of the main peak of the control solution |
| Related substance | |
| Impurity B | 0.1% max |
| Impurity C | 0.1% max |
| Impurity D | 0.1% max |
| Impurity E | 0.1% max |
| Single unknown impurity | 0.2% max |
| Total Impurities | 1.0% max |
| Optical isomer | Impurity A 1% max |
| Residual Solvents | |
| Methanol | 0.3% max |
| Isopropanol | 0.5% max |
| MTBE | 0.5% max |
| EA | 0.5% max |
| THF | 0.072% max |
| 1, 4-dioxane | 0.038% max |
| DMSO | 0.5% max |
| Loss on drying | 0.5% max |
Applications
1. Myelofibrosis
Ruxolitinib丨CAS 941678-49-5 is a type of bone marrow cancer that disrupts normal blood cell production, leading to an overproduction of scar tissue (fibrosis) in the bone marrow. This fibrosis impairs the ability of the bone marrow to produce blood cells and can cause anemia, spleen and liver enlargement, and a variety of other symptoms.
● Treatment: Ruxolitinib is approved for the treatment of myelofibrosis in patients with intermediate or high-risk disease. It helps reduce splenomegaly (enlarged spleen), improve symptoms related to bone marrow fibrosis (such as fatigue and pain), and improve blood counts.
● Benefits: Ruxolitinib has been shown to significantly reduce spleen size and improve symptoms associated with myelofibrosis, leading to a better quality of life for patients.
2. Polycythemia Vera
Polycythemia vera is a myeloproliferative disorder characterized by the overproduction of red blood cells, which can lead to complications such as thrombosis (blood clots) and splenomegaly.
● Treatment: Ruxolitinib is used for the treatment of polycythemia vera in patients who have resistant or intolerant to first-line therapy, including hydroxyurea. It helps control the symptoms of the disease, such as itching, fatigue, and headaches, and can also reduce the need for phlebotomies (blood draws) and control hematocrit levels.
● Benefits: In patients with polycythemia vera, ruxolitinib has been shown to effectively reduce red blood cell production and improve hematologic parameters, helping to lower the risk of thrombotic events and improving overall disease management.
3. Graft-Versus-Host Disease (GVHD)
GVHD occurs when the transplanted immune cells from a donor recognize the recipient's tissue as foreign and attack it. This condition is a serious complication of stem cell or bone marrow transplants.
● Treatment: Ruxolitinib is being investigated as a treatment for acute and chronic GVHD, particularly in patients who do not respond well to corticosteroid therapy. By suppressing the immune response, ruxolitinib helps to alleviate the inflammation and damage caused by the donor immune cells.
● Benefits: Early clinical trials have demonstrated promising results in controlling GVHD symptoms, including reducing the inflammatory response and improving patient outcomes when conventional treatments are inadequate.
4. Autoimmune Diseases
Ruxolitinib丨CAS 941678-49-5 is also being explored for the treatment of various autoimmune conditions where the immune system is overactive, leading to chronic inflammation and tissue damage. These diseases include conditions like rheumatoid arthritis and psoriasis.
● Treatment: In autoimmune conditions, ruxolitinib may help reduce inflammation by inhibiting the overactive cytokine signaling pathways that contribute to tissue damage.
● Benefits: While not yet FDA-approved for these indications, ruxolitinib has shown potential in clinical trials for reducing disease activity and improving symptoms in patients with autoimmune disorders.
Benefits
1. Improved Quality of Life for Myelofibrosis Patients
For patients with myelofibrosis, ruxolitinib significantly improves quality of life by reducing splenomegaly, alleviating symptoms like fatigue and pain, and improving blood counts. The ability to manage these symptoms can help patients feel better and maintain daily activities.
2. Reduced Risk of Thrombosis in Polycythemia Vera
In polycythemia vera, ruxolitinib reduces hematocrit levels and decreases the risk of blood clots (thrombosis). This benefit is crucial for preventing severe complications such as strokes, heart attacks, and deep vein thrombosis (DVT).
3. Cytokine Inhibition
Ruxolitinib's ability to block cytokine signaling has therapeutic implications beyond myelofibrosis and polycythemia vera. By inhibiting JAK1 and JAK2, it can modulate immune responses, reduce inflammation, and limit tissue damage in conditions such as autoimmune diseases and GVHD.
4. Tolerability and Efficacy
Ruxolitinib丨CAS 941678-49-5 has shown to be effective in treating difficult-to-manage diseases like myelofibrosis and polycythemia vera, especially in patients who are resistant to or intolerant of other treatments. Its oral administration makes it more convenient than other systemic treatments, such as chemotherapy or injectable biologics.
5. Potential for Combination Therapy
Ruxolitinib can also be used in combination with other therapies, such as immunosuppressive drugs or chemotherapy, to improve treatment outcomes in certain diseases like GVHD and autoimmune disorders.
Conclusion
Ruxolitinib丨CAS 941678-49-5 is a highly effective JAK1/2 inhibitor with significant therapeutic applications in the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. By modulating cytokine signaling, it provides a powerful option for patients with these challenging conditions. Additionally, its potential in treating autoimmune diseases and its effectiveness in managing complications like splenomegaly and thrombosis highlight its growing importance in the field of hematology and immunology.
Previous
Next
Conclusion
A concise summary and suitability assessment for this product is available on request. Contact our team to discuss whether it fits your process and quality requirements.